The valuation is a non-binding third-party estimate and does not reflect realized commercial traction. Monitor for actual operational launch, regulatory permits, and revenue generation from the UAE hub. Given the company's history of reverse splits and poor stock performance, treat this as a low-conviction narrative catalyst until concrete financials emerge.
Price Chart
Executive Summary
NewGenIvf announced a Big Four valuation of ~$19 million for its planned UAE cell sorting and cytometry leasing business, building on a prior IP valuation of $17.9 million, and appointed Nadeem Malik as Senior Strategic Advisor to lead GCC expansion. The press release is forward-looking with no current revenue or operational milestones from this initiative, making it a non-material event for a micro-cap stock with a history of poor trading performance.
Key Facts
- Big Four valuation assigns a midpoint equity value of ~$19 million (as of May 31, 2026) for the planned UAE cell sorting and cytometry leasing entity.
- Prior Big Four valuation of the company's advanced cytometry IP was $17.9 million (October 2025).
- Nadeem Malik appointed Senior Strategic Advisor; he was former CEO of Genetics and IVF Institute and President of Fairfax Cryobank.
- UAE IVF market projected to grow from ~$270 million (2024) to ~$444 million by 2030 (CAGR ~8.5%, per TechSci Research).
- Company had only 240,622 Class A shares outstanding as of December 31, 2025 (after multiple reverse stock splits), with a current market cap of ~$5 million.
Financial Impact
Non-cash valuation event; no revenue or cash flow impact reported. The $19 million midpoint equity value is ~3.8x current market cap but represents a planned entity with no operating history.
Risk Factors
- Execution risk: the planned UAE entity requires regulatory permits, operational setup, and market adoption that may not materialize.
- Dilution risk: the company has a history of reverse stock splits and may need additional capital to fund expansion.
- Geopolitical and regulatory risk in the UAE/GCC region.
- Forward-looking statements are based on third-party market projections that may not be accurate.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-075253 |
| Document: ea0297090-6k_newgenivf.htm | 0001213900-26-075253 |
| Document: 0001213900-26-075253-index-headers.html | 0001213900-26-075253 |
| Document: 0001213900-26-075253-index.html | 0001213900-26-075253 |
| Document: 0001213900-26-075253.txt | 0001213900-26-075253 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 6-K | $0.1884 $0.1489 | ▼ −20.97% | ▼ −19.79% | $1.16 (+515.71%) |
Oct 7, 2026 19d ago | 6-K | $0.0811 $0.0721 | ▲ +11.10% | ▲ +11.70% | $1.16 (−1330.33%) |
Oct 7, 2026 19d ago | 6-K | $0.1060 $0.0811 | ▼ −23.49% | ▼ −23.07% | $1.16 (+994.34%) |
Oct 6, 2026 20d ago | SC 13D/A | $0.0987 $0.1060 | ▲ +7.40% | ▲ +7.64% | $1.16 (+1075.28%) |
Oct 5, 2026 21d ago | 6-K | $0.1100 $0.0987 | ▲ +10.27% | ▲ +10.82% | $1.16 (−954.55%) |
Sep 30, 2026 26d ago | Press Release | $0.1680 $0.1010 | ▲ +39.88% | ▲ +40.06% | $1.16 (−590.48%) |
Sep 30, 2026 26d ago | 424B4 | $5.38 $3.23 | ▲ +39.88% | ▲ +40.06% | $1.16 (+78.42%) |
Sep 29, 2026 28d ago | EFFECT | $0.0720 $0.1680 | ▼ −133.33% | ▼ −133.54% | $1.16 (−1511.11%) |
Sep 28, 2026 28d ago | Press Release | $0.0720 $0.1680 | ▼ −133.33% | ▼ −133.54% | $1.16 (−1511.11%) |
Sep 2, 2026 7w ago | Insider Cluster | $1.21 $1.18 | ▼ −2.48% | ▼ −3.53% | $1.16 (−4.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers